177Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results

Conclusion: This initial report provides clinical evidence of the feasibility of treatment of ductal pancreatic adenocarcinoma using 177Lu-3BP-227.

Source: Journal of Nuclear Medicine - May 1, 2018 Category: Nuclear Medicine Authors: Baum, R. P., Singh, A., Schuchardt, C., Kulkarni, H. R., Klette, I., Wiessalla, S., Osterkamp, F., Reineke, U., Smerling, C. Tags: Clinical Source Type: research